BioMarin Pharma (BMRN) Misses Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BioMarin Announces Fourth Quarter and Full Year 2015 Financial Results
February 25, 2016 4:02 PM EST- Full-year 2015 Total BioMarin Revenue Increases 18.8% to $889.9 million Year-over-Year
- Vimizim Net Product Revenue Contributes Over $228 million to 2015 Top-line
- Full-year 2016 Total BioMarin Revenue Guidance of Between $1.05 billion to $1.10 billion
- Company Anticipates Non-GAAP Breakeven or Better in 2017 Under all E.U. Outcomes with Kyndrisa
Financial Highlights ($ in millions, except per share data, unaudited)
  Three Months Ended December 31,  Twelve Months... More